Form 4: Edgewise CBO's Equity Compensation & Tax Sale

Edgewise Therapeutics' Chief Business Officer, Behrad Derakhshan, reported routine equity compensation grants and a sell-to-cover transaction for tax obligations.

Summary

• Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, Inc. (EWTX), reported changes in his beneficial ownership.
• He acquired 5,781 shares of common stock on August 12, 2025, resulting from the vesting of Restricted Stock Units (RSUs).
• Concurrently, he sold 2,491 shares of common stock at an average price of $13.3924 per share to cover statutory tax withholding obligations related to the RSU vesting.
• Following these transactions, his direct beneficial ownership of common stock is 23,645 shares.
• He was granted 30,000 new Restricted Stock Units (RSUs) on August 12, 2025, vesting in four equal annual installments starting August 12, 2026.
• He also received a grant of 180,000 stock options on August 12, 2025, with an exercise price of $13.39 per share, vesting monthly over 48 months beginning September 12, 2025.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation and tax-related sales, which are generally neutral. The grant of new equity incentives is a positive sign of continued executive alignment and retention, outweighing the minor tax-related sale.

Positives

• Grant of 30,000 new Restricted Stock Units (RSUs) and 180,000 stock options aligns the Chief Business Officer's interests with long-term shareholder value.
• The equity grants demonstrate continued commitment to the executive's role and performance.

Negatives

• A sale of 2,491 shares of common stock, even for tax purposes, reduces the Chief Business Officer's direct ownership stake.

Risks

• The value of the newly granted RSUs and stock options is subject to the future performance and volatility of Edgewise Therapeutics' common stock.
• The "sell-to-cover" transaction highlights the tax implications of equity compensation for executives.

Future Outlook

The vesting schedules for the newly granted Restricted Stock Units and stock options extend through August 2035, indicating a long-term incentive structure for the Chief Business Officer tied to future company performance.

Management Comments

• The sale of 2,491 shares was explicitly stated to satisfy minimum statutory tax withholding obligations and does not represent a discretionary sale by the Reporting Person.

Industry Context

This filing represents a routine executive compensation event common in the biotechnology and pharmaceutical industries, where equity grants are a standard component of executive pay packages designed to align management incentives with shareholder interests and retain key talent.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting schedules, is consistent with typical practices for executives in publicly traded biotechnology companies.
• The 'sell-to-cover' mechanism for tax withholding is also a standard industry practice to manage tax liabilities arising from equity vesting, observed across companies like Moderna, BioNTech, and Regeneron Pharmaceuticals.

Stakeholder Impact

• Shareholders: The grant of new equity incentives aligns the Chief Business Officer's interests with shareholders, potentially encouraging long-term value creation. The tax-related sale is a minor, non-discretionary event.

Next Steps

• Continued vesting of 30,000 Restricted Stock Units in four equal annual installments beginning August 12, 2026.
• Continued monthly vesting of 180,000 stock options (1/48th each month) beginning September 12, 2025.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Stock Options, Executive Compensation, Behrad Derakhshan, Chief Business Officer